Serum Concentrations of BDNF in Adolescents with Metabolic Syndrome: a Case-control Study Between Normal - BMI Adolescents and Adolescents with Obesity

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 2023 Aug 7

PMID 37548699

Authors

Flora Bacopoulou

Nikolaos G Angelopoulos

Stavroula Papadodima

Despoina Apostolaki

Aimilia Mantzou

Eleni Koniari

Vasiliki Efthymiou

Artemis Tsitsika

Dimitrios Vlachakis

Evangelia Charmandari

Charikleia Stefanaki

Affiliations

Soon will be listed here.

Abstract

Brain-Derived Neurotrophic Factor (BDNF) has been linked to various conditions of the cardiovascular and nervous systems. Scarce data exist about the concentrations of BDNF in children and adolescents in relation with obesity and metabolic syndrome (MetS). The aim of this study was to examine the serum BDNF concentrations in adolescents with metabolic syndrome and according to their body mass index (BMI) status. This was a case-control study, assessing BDNF concentrations between adolescents with MetS (with obesity vs. normal-BMI), in relation to sex, anthropometric, metabolic and endocrine parameters. Participants included male and female adolescents, whose anthropometric and metabolic panel, as well as serum BDNF concentrations were measured. A total of 59 adolescents (obesity: 29; normal-BMI: 30) were included in the study. Increased serum BDNF concentrations were observed in MetS adolescents with obesity when compared with normal-BMI adolescents (p < 0.001). Males exhibited higher concentrations of BDNF than females (p = 0.045). The sample was further divided into four categories by sex and BMI status, with normal-BMI females exhibiting significantly lower BDNF concentrations than females and males with obesity(p = 0.005). In the entire study sample, serum BDNF concentrations correlated positively with BMI z-scores, however, this statistical significance was preserved only in the females of the sample. No statistical difference was observed between males of different BMI z-scores categories. Conclusion: Obesity appeared as a major factor for increased serum BDNF concentrations in adolescents with MetS (vs. normal-BMI), with a higher impact on BDNF concentrations in females than males. What is Known: • The brain-derived neurotrophic factor (BDNF) is involved in metabolic syndrome in adults but data in adolescents are scarce. What is New: • Obesity (vs. normal BMI) was a major factor for increased serum BDNF in adolescents with metabolic syndrome. • Obesity had a higher impact on BDNF concentrations in females than males with metabolic syndrome.

References

Marosi K, Mattson M . BDNF mediates adaptive brain and body responses to energetic challenges. Trends Endocrinol Metab. 2013; 25(2):89-98. PMC: 3915771. DOI: 10.1016/j.tem.2013.10.006. View

Leal G, Bramham C, Duarte C . BDNF and Hippocampal Synaptic Plasticity. Vitam Horm. 2017; 104:153-195. DOI: 10.1016/bs.vh.2016.10.004. View

Yoshimura R, Sugita-Ikenouchi A, Hori H, Umene-Nakano W, Hayashi K, Katsuki A . A close correlation between plasma and serum levels of brain-derived neurotrophic factor (BDNF) in healthy volunteers. Int J Psychiatry Clin Pract. 2014; 14(3):220-2. DOI: 10.3109/13651501003748560. View

Mori Y, Tsuji M, Oguchi T, Kasuga K, Kimura A, Futamura A . Serum BDNF as a Potential Biomarker of Alzheimer's Disease: Verification Through Assessment of Serum, Cerebrospinal Fluid, and Medial Temporal Lobe Atrophy. Front Neurol. 2021; 12:653267. PMC: 8102980. DOI: 10.3389/fneur.2021.653267. View

Emon M, Das R, Nishuty N, Qusar M, Bhuiyan M, Islam M . Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case-control study with or without antidepressant therapy. BMC Res Notes. 2020; 13(1):83. PMC: 7035767. DOI: 10.1186/s13104-020-04952-3. View

Azoulay D, Urshansky N, Karni A . Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol. 2008; 195(1-2):186-93. DOI: 10.1016/j.jneuroim.2008.01.010. View

Huang Y, Yun W, Zhang M, Luo W, Zhou X . Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson's disease or essential tremor. J Int Med Res. 2018; 46(4):1477-1485. PMC: 6091839. DOI: 10.1177/0300060517748843. View

Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya K, Sekine Y . Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(8):1529-31. DOI: 10.1016/j.pnpbp.2006.06.018. View

Ruiz-Gonzalez D, Hernandez-Martinez A, Valenzuela P, Morales J, Soriano-Maldonado A . Effects of physical exercise on plasma brain-derived neurotrophic factor in neurodegenerative disorders: A systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev. 2021; 128:394-405. DOI: 10.1016/j.neubiorev.2021.05.025. View

10.

Motamedi S, Karimi I, Jafari F . The interrelationship of metabolic syndrome and neurodegenerative diseases with focus on brain-derived neurotrophic factor (BDNF): Kill two birds with one stone. Metab Brain Dis. 2017; 32(3):651-665. DOI: 10.1007/s11011-017-9997-0. View

11.

Roh H, So W . The effects of aerobic exercise training on oxidant-antioxidant balance, neurotrophic factor levels, and blood-brain barrier function in obese and non-obese men. J Sport Health Sci. 2018; 6(4):447-453. PMC: 6189263. DOI: 10.1016/j.jshs.2016.07.006. View

12.

Krabbe K, Nielsen A, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C . Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2006; 50(2):431-8. DOI: 10.1007/s00125-006-0537-4. View

13.

Barbosa A, Pratesi R, Paz G, Dos Santos M, Uenishi R, Nakano E . Assessment of BDNF serum levels as a diagnostic marker in children with autism spectrum disorder. Sci Rep. 2020; 10(1):17348. PMC: 7566481. DOI: 10.1038/s41598-020-74239-x. View

14.

Han J, Muehlbauer M, Cui H, Newgard C, Haqq A . Lower brain-derived neurotrophic factor in patients with prader-willi syndrome compared to obese and lean control subjects. J Clin Endocrinol Metab. 2010; 95(7):3532-6. PMC: 2928902. DOI: 10.1210/jc.2010-0127. View

15.

Margoni D, Michalakakou K, Angeli E, Pervanidou P, Kanaka-Gantenbein C, Chrousos G . Serum brain-derived neurotrophic factor in children with coeliac disease. Eur J Clin Invest. 2018; 48(5):e12916. DOI: 10.1111/eci.12916. View

16.

Zimmet P, Alberti K, Kaufman F, Tajima N, Silink M, Arslanian S . The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. 2007; 8(5):299-306. DOI: 10.1111/j.1399-5448.2007.00271.x. View

17.

Bacopoulou F, Efthymiou V, Landis G, Rentoumis A, Chrousos G . Waist circumference, waist-to-hip ratio and waist-to-height ratio reference percentiles for abdominal obesity among Greek adolescents. BMC Pediatr. 2015; 15:50. PMC: 4446827. DOI: 10.1186/s12887-015-0366-z. View

18.

De Sanctis V, Soliman A, Daar S, Tzoulis P, Di Maio S, Kattamis C . Oral glucose tolerance test: Ηow to maximize its diagnostic value in children and adolescents. Acta Biomed. 2022; 93(5):e2022318. PMC: 9686143. DOI: 10.23750/abm.v93i5.13615. View

19.

Bartoli E, Fra G, Carnevale Schianca G . The oral glucose tolerance test (OGTT) revisited. Eur J Intern Med. 2011; 22(1):8-12. DOI: 10.1016/j.ejim.2010.07.008. View

20.

Cole T, Bellizzi M, Flegal K, Dietz W . Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000; 320(7244):1240-3. PMC: 27365. DOI: 10.1136/bmj.320.7244.1240. View